Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. HRS-5041 is a Proteolysis Targeting Chimeras (PROTAC) targeting androgen receptors. This is a phase Ib, open-label, multi-center study to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-20093 combination with HRS-5041 in patients with advanced prostate cancer.

Trial Details

NCT ID
NCT07115446
Phase
PHASE1
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • HS-20093
  • HRS-5041
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Men greater than or equal to 18 years.
  • Voluntarily to participate, Signed and dated Informed Consent Form.
  • Patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after at least one type of novel hormonal therapy (standard tr…
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →